Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Almac Offering TruSight Tumor Profiling Next-Generation Sequencing Service

Published: Monday, September 30, 2013
Last Updated: Sunday, September 29, 2013
Bookmark and Share
TruSight Tumor™ panel is specifically designed for use with FFPE samples.

Almac has announced that they are now offering a Tumor Profiling service running Illumina’s next-generation sequencing (NGS) TruSight Tumor™ panel as part of their biomarker discovery, development and delivery solutions.

Almac, a personalized medicine company with CAP accredited and CLIA certified laboratories, extends their portfolio of services by offering TruSight Tumor™ to complement its current range of RNA, DNA and protein based technologies for biomarker analysis.

Almac is currently running many bespoke diagnostic assays for pharma customers for early phase clinical trial enrichment.

The TruSight Tumor™ panel enables additional profiling of these patient samples to provide Almac’s pharma partners with further important information on emerging biomarkers that may also impact drug response.

The TruSight Tumor™ panel was developed by Illumina for their MiSeq® system, allowing targeted DNA sequencing and reporting on the mutation status of 26 genes which are most commonly mutated in solid tumors including lung, colon, ovarian, melanoma and gastric cancers.

One of Almac’s key strengths is many years of experience in working with formalin fixed paraffin embedded (FFPE) tissue.

The TruSight Tumor™ panel is specifically designed for use with FFPE samples, and enables the highest levels of sensitivity for mutation detection with limited DNA input requirements.

“Almac is committed to the development of personalized medicine through the delivery of a wide range of innovative solutions. We are pleased to announce the expansion of our NGS service to include TruSight Tumor™” said Professor Paul Harkin, President and Managing Director of Almac’s Diagnostic business unit.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac and ESMS Global Collaborate to Offer Unique Clinical Trial Support
Sponsors requesting 24/7 medical support & emergency unblinding can save time and money.
Friday, November 28, 2014
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Thursday, November 13, 2014
Almac Introduce Flexible Clinical Trial Direct to Patient Solution
Available for clinical studies conducted throughout the US & Canada.
Friday, October 31, 2014
Almac Expand its UK Commercial Packaging Facility
Company makes further significant co-investment to meet Japanese client demand for humidity controlled blister packaging.
Friday, October 10, 2014
Almac’s AADx Gene Expression Marker Attracts Significant Commercial Interest from Pharma
Evaluation in colorectal, breast and lung cancer to follow.
Thursday, June 26, 2014
Almac Profits Up 30%
Company will open a new clinical trial secondary packaging facility in Singapore.
Wednesday, May 28, 2014
Almac Achieves Double Success at Business Award Ceremony
Presented with both Excellence in Innovation & Technology.
Tuesday, April 01, 2014
Almac Expands Asia Pacific Operations
Comprehensive support for trials of any size or complexity whether they originate in Asia or include Asian sites.
Wednesday, March 12, 2014
Almac Wins Laboratory Team of the Year at The Irish Laboratory Awards 2013
The awards held to recognize the success and achievements of Ireland’s internationally renowned scientists.
Thursday, December 12, 2013
Almac Announces Release of Enhanced 3PL Customer Billing Application
Company further enhance 3rd Party Logistics commercial support services for niche / orphan drugs.
Tuesday, November 19, 2013
Almac Increase Global Stability Storage Capacity
Company has completed a $2m investment programme.
Tuesday, November 05, 2013
Richard Segiel, Jr. Joins Almac as Vice President of US Business Development
Richard will focus on developing new business, maintaining existing business, and developing partnerships.
Wednesday, October 30, 2013
Almac’s Strengthened Facilities Accommodates Demand of Late Stage API Manufacture
Facility upgrade include installation of two 1,000L reactors and pressure filter dryer.
Friday, October 25, 2013
Almac Invests to Accelerate Formulation Development Services
Almac expands its pharmaceutical development service offering with an investment in excess of $10m.
Thursday, October 24, 2013
Almac Receives Appreciation Award from OAPI
Celine Bradley receives award of appreciation from Brent Kelly.
Friday, August 02, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!